Skip to content

Hydroxycarbamide

Hydroxycarbamide (Hydrea) is an anticancer medicine used for chronic myeloid leukaemia, head and neck cancer, and sickle cell anaemia. It is the only formulation listed in this catalogue.

Hydrea

Chronic Myeloid Leukaemia, Head and Neck Cancer

500mg

Hydroxycarbamide tablets for chronic myeloid leukaemia and certain head and neck cancers. It works by stopping cancer cells from dividing.

From$2.12/ tabletView

Key points

  • Hydroxycarbamide is a cytotoxic antimetabolite that interferes with DNA production in rapidly dividing cells.
  • The only listed formulation is a 500mg tablet, supplied by originator Bristol-Myers Squibb under the brand Hydrea.
  • Hydroxycarbamide is also used for sickle cell anaemia, where it reduces the frequency of painful crises.

Common questions about Hydroxycarbamide

Why does Hydroxycarbamide come as a 500mg tablet only?

The catalogue contains one formulation: a 500mg tablet sold under the brand Hydrea. It falls under Oncology Support, the category for cancer-related treatments.

What conditions is Hydrea prescribed for?

Hydrea is listed for Chronic Myeloid Leukaemia, Head and Neck Cancer, and sickle cell anaemia.

Further reading